AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2014

Liedtke, Cornelia; Thill, Marc; Hanf, Volker; Schütz, Florian

doi:10.1159/000363591

Cited by 9 publications

(20 citation statements)

References 95 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An increasing number of young long-term survivors have the prospect of a ‘normal' life after being diagnosed with and treated for cancer. Whereas earlier curing cancer was by far the most outstanding task, today oncology is increasingly confronted with issues concerning the life after cancer (‘survivorship') and the quality of life [1,3,22,23,24]. …”

Section: Fertility Protection and Family Planningmentioning

confidence: 99%

“…Preserving fertility through preventive action seems to positively influence the quality of life of those affected [30]. Therefore, the AGO recommends that all patients who have not yet completed their family planning should be advised on ways of preserving fertility before oncological therapy [1,3]. Unfortunately, the aspect of fertility preservation is not taken into account sufficiently when planning oncological therapy.…”

Section: Fertility Protection and Family Planningmentioning

confidence: 99%

“…Combination regimens used as adjuvant treatment have different rates of premature menopause. High cumulative doses of alkylating agents after the age of 35 years are associated with a high probability of premature menopause [1,2,3,24,29,33]. Strategies against premature ovarian failure have been researched extensively over the last decade.…”

Section: Fertility Protection and Family Planningmentioning

confidence: 99%

“…The validity of the study, however, suffers from the fact that no data for evaluation were available for 38% of the study participants [36]. Therefore, the AGO evaluates the application of GnRH to achieve ovarian protection with restraint and as an option for individual cases only [1,3]. …”

Section: Fertility Protection and Family Planningmentioning

confidence: 99%

“…There is no doubt that these women benefit from chemo-, endocrine and anti-HER2 therapy to a similar degree as older women. Surgery and radiation therapy for these patients also follow the same recommendations as those for women aged 40 years or older [1,2,3,4]. However, the life expectancy of young women is longer, thereby extending the time in which the breast cancer may recur.…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Treatment Modification in Young Breast Cancer Patients

Scharl

Salterberg²,

Untch³

et al. 2016

Oncol Res Treat

Self Cite

View full text Add to dashboard Cite

Patients not older than 40 years are referred to as young patients. These women benefit from chemo-, endocrine and anti-HER2 therapy to a similar degree as older women. Surgery and radiation therapy also follow the same recommendations. This manuscript deals with the following topics that need special consideration in young women: endocrine therapy and ovarian suppression; fertility protection and family planning; and genetic counselling. There is an on-going debate on whether tamoxifen is sufficient as an endocrine treatment in young patients with endocrine-responsive tumours or whether suppression of ovarian function in combination with tamoxifen or aromatase inhibitor should be preferred. Recent data suggest a benefit from ovarian suppression plus exemestane in women of 35 years or younger with high-risk breast cancer. However, increased side effects bear the risk of lesser compliance, which eventually results in higher mortality. Child bearing is nowadays frequently postponed to the 4th decade of life, thereby increasing the number of women who have not yet finished their reproductive desires when diagnosed with breast cancer. These patients are in urgent need of counselling for fertility protection. Breast cancer diagnosis at young age is an indication for a possible mutation in breast cancer susceptibility genes. This has an impact on the cancer risk of the whole family, especially the offspring. Drugs that are specifically targeted to cancer cells with genetic alterations that impair DNA repair are already entering the arsenal of oncologists.

show abstract

Section: Fertility Protection and Family Planningmentioning

confidence: 99%

Section: Fertility Protection and Family Planningmentioning

confidence: 99%